Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research

See what CB Insights has to offer


Acquired | Acquired

About Topstone Research

Topstone Research is a Canadian-based specialty contract research organization (CRO) with Phase II-IV services.

Topstone Research Headquarter Location

1 Eva Road Suite 111

Toronto, Ontario, M9C 4Z5,



Latest Topstone Research News

CROs ‘combine forces’ to meet demand from biopharma customers

Oct 3, 2018

By Melissa Fassbender Veristat’s acquisition of Topstone enhances the CRO’s capabilities within several areas and boosts its employee count to 300 across six offices. Veristat, a full-service clinical research organization (CRO) based in Southborough, MA has completed its acquisition of Topstone Research, a Canadian-based specialty contract research organization (CRO) providing Phase II-IV services. Veristat CEO Patrick Flanagan said the company had been looking to broaden its clinical operations capabilities. “Our customers are moving their therapies to pivotal trials quickly and have continued to ask us for more of the services we provide and additional, complementary clinical services,”​ he told us. The acquisition bolsters Veristat’s core therapeutic areas of excellence and broadens its therapeutic expertise with respiratory and dermatology, Flanagan said. “Additionally, Topstone adds patient recruitment and retention support, a site engagement team, and medical safety and monitoring expertise to support investigators and sites with study conduct in an ethical, patient safety-focused approach,”​ he added. Topstone will be integrated Veristat’s current monitoring and site management organization transitioning to the Veristat name and brand over the coming months. The combined team now consists of nearly 300 experts located in six offices. Topstone’s current CEO, Shaheen Limbada, will become Veristat’s executive vice president of clinical operations with both companies’ clinical operations teams uniting under his leadership. As for next steps, Flanagan said the acquisition is part of the growth strategy that Veristat will continue to pursue to improve and expand its capabilities to new service offerings and geographies, “to serve the growing demands of our emerging and small to mid-sized biopharmaceutical customers.”​ “Where an opportunity presents itself to combine with a company which shares Veristat’s mission to help clients develop life-enhancing therapies and our commitment to delivering high-quality services which make a difference we will seek to combine forces,”​ he said. Copyright - Unless otherwise stated all contents of this web site are © 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.